Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial
This study was conducted to demonstrate the efficacy and safety of LixiLan (iGlarLixi), a novel, titratable, fixed-ratio combination of insulin glargine (iGlar) (100 units) and lixisenatide, compared with iGlar in patients with type 2 diabetes inadequately controlled on basal insulin with or without...
Gespeichert in:
| Veröffentlicht in: | Diabetes care 2016-11, Vol.39 (11), p.1972-1980 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1980 |
|---|---|
| container_issue | 11 |
| container_start_page | 1972 |
| container_title | Diabetes care |
| container_volume | 39 |
| creator | Aroda, Vanita R Rosenstock, Julio Wysham, Carol Unger, Jeffrey Bellido, Diego González-Gálvez, Guillermo Takami, Akane Guo, Hailing Niemoeller, Elisabeth Souhami, Elisabeth Bergenstal, Richard M |
| description | This study was conducted to demonstrate the efficacy and safety of LixiLan (iGlarLixi), a novel, titratable, fixed-ratio combination of insulin glargine (iGlar) (100 units) and lixisenatide, compared with iGlar in patients with type 2 diabetes inadequately controlled on basal insulin with or without up to two oral glucose-lowering agents.
After a 6-week run-in when iGlar was introduced and/or further titrated, and oral antidiabetic drugs other than metformin were stopped, 736 basal insulin-treated patients (mean diabetes duration 12 years, BMI 31 kg/m
) were randomized 1:1 to open-label, once-daily iGlarLixi or iGlar, both titrated to fasting plasma glucose |
| doi_str_mv | 10.2337/dc16-1495 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1847879066</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4248783501</sourcerecordid><originalsourceid>FETCH-LOGICAL-c414t-372198c0280ce1212be93d80b29d2bbf0ce850872fd70d2cb0c30a36b9ea2a943</originalsourceid><addsrcrecordid>eNpdkctu1TAQhiMEoofCghdAltiARMCXXGx2cGhLpSBQCetoYk_AleOc2onU8Jw8EA69LFjZmvnm0y_9Wfac0bdciPqd0azKWaHKB9mOKVHmZVnIh9mOplleKsWPsicxXlJKi0LKx9kRr6uSqrreZX9OhsFq0CsBb8h3GHBeyTSQxl7bBvwbAqS1c4AZeofk1F6jyS9gthPZT2Nv_fb128G5j4uznpw5CD-tR_LNLfGfJuJGGSRp264HJJx8stDjjDFdgcGrBWZ0azL6OUzOoSHJ-REiuHvtlu4LzsMURuvfk_YX3kXMG3KRttNof6fDNlhwT7NHA7iIz27f4-zH6Um7_5w3X8_O9x-aXBesmHNRc6akplxSjYwz3qMSRtKeK8P7fkhTWVJZ88HU1HDdUy0oiKpXCBxUIY6zVzfeQ5iuFoxzN9qo0TnwOC2xY7KoZa1oVSX05X_o5bQEn9IlSkglS1GxRL2-oXSYYgw4dIdgRwhrx2i3Vd1tVXdb1Yl9cWtc-hHNPXnXrfgLJ2WlgA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1838985361</pqid></control><display><type>article</type><title>Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Aroda, Vanita R ; Rosenstock, Julio ; Wysham, Carol ; Unger, Jeffrey ; Bellido, Diego ; González-Gálvez, Guillermo ; Takami, Akane ; Guo, Hailing ; Niemoeller, Elisabeth ; Souhami, Elisabeth ; Bergenstal, Richard M</creator><creatorcontrib>Aroda, Vanita R ; Rosenstock, Julio ; Wysham, Carol ; Unger, Jeffrey ; Bellido, Diego ; González-Gálvez, Guillermo ; Takami, Akane ; Guo, Hailing ; Niemoeller, Elisabeth ; Souhami, Elisabeth ; Bergenstal, Richard M ; LixiLan-L Trial Investigators ; on behalf of the LixiLan-L Trial Investigators</creatorcontrib><description>This study was conducted to demonstrate the efficacy and safety of LixiLan (iGlarLixi), a novel, titratable, fixed-ratio combination of insulin glargine (iGlar) (100 units) and lixisenatide, compared with iGlar in patients with type 2 diabetes inadequately controlled on basal insulin with or without up to two oral glucose-lowering agents.
After a 6-week run-in when iGlar was introduced and/or further titrated, and oral antidiabetic drugs other than metformin were stopped, 736 basal insulin-treated patients (mean diabetes duration 12 years, BMI 31 kg/m
) were randomized 1:1 to open-label, once-daily iGlarLixi or iGlar, both titrated to fasting plasma glucose <100 mg/dL (<5.6 mmol/L) up to a maximum dose of 60 units/day. The primary outcome was change in HbA
levels at 30 weeks.
HbA
decreased from 8.5% (69 mmol/mol) to 8.1% (65 mmol/mol) during the run-in period. After randomization, iGlarLixi showed greater reductions in HbA
from baseline compared with iGlar (-1.1% vs. -0.6%, P < 0.0001), reaching a mean final HbA
of 6.9% (52 mmol/mol) compared with 7.5% (58 mmol/mol) for iGlar. HbA
<7.0% (53 mmol/mol) was achieved in 55% of iGlarLixi patients compared with 30% on iGlar. Mean body weight decreased by 0.7 kg with iGlarLixi and increased by 0.7 kg with iGlar (1.4 kg difference, P < 0.0001). Documented symptomatic hypoglycemia (≤70 mg/dL) was comparable between groups. Mild gastrointestinal adverse effects were very low but more frequent with iGlarLixi.
Compared with iGlar, a substantially higher proportion of iGlarLixi-treated patients achieved glycemic targets with a beneficial effect on body weight, no additional risk of hypoglycemia, and low levels of gastrointestinal adverse effects in inadequately controlled, basal insulin-treated, long-standing type 2 diabetes.</description><identifier>ISSN: 0149-5992</identifier><identifier>EISSN: 1935-5548</identifier><identifier>DOI: 10.2337/dc16-1495</identifier><identifier>PMID: 27650977</identifier><identifier>CODEN: DICAD2</identifier><language>eng</language><publisher>United States: American Diabetes Association</publisher><subject>Aged ; Blood Glucose - metabolism ; Body Mass Index ; Body Weight ; Clinical trials ; Diabetes ; Diabetes Mellitus, Type 2 - drug therapy ; Dose-Response Relationship, Drug ; Drug Combinations ; Drug Evaluation, Preclinical ; Endpoint Determination ; Female ; Glycated Hemoglobin A - metabolism ; Humans ; Hypoglycemic Agents - administration & dosage ; Hypoglycemic Agents - therapeutic use ; Insulin ; Insulin - therapeutic use ; Insulin Glargine - administration & dosage ; Insulin Glargine - therapeutic use ; Male ; Medical treatment ; Metformin - therapeutic use ; Middle Aged ; Peptides - administration & dosage ; Peptides - therapeutic use ; Pharmaceuticals ; Side effects ; Treatment Outcome</subject><ispartof>Diabetes care, 2016-11, Vol.39 (11), p.1972-1980</ispartof><rights>2016 by the American Diabetes Association.</rights><rights>Copyright American Diabetes Association Nov 1, 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c414t-372198c0280ce1212be93d80b29d2bbf0ce850872fd70d2cb0c30a36b9ea2a943</citedby><cites>FETCH-LOGICAL-c414t-372198c0280ce1212be93d80b29d2bbf0ce850872fd70d2cb0c30a36b9ea2a943</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27650977$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aroda, Vanita R</creatorcontrib><creatorcontrib>Rosenstock, Julio</creatorcontrib><creatorcontrib>Wysham, Carol</creatorcontrib><creatorcontrib>Unger, Jeffrey</creatorcontrib><creatorcontrib>Bellido, Diego</creatorcontrib><creatorcontrib>González-Gálvez, Guillermo</creatorcontrib><creatorcontrib>Takami, Akane</creatorcontrib><creatorcontrib>Guo, Hailing</creatorcontrib><creatorcontrib>Niemoeller, Elisabeth</creatorcontrib><creatorcontrib>Souhami, Elisabeth</creatorcontrib><creatorcontrib>Bergenstal, Richard M</creatorcontrib><creatorcontrib>LixiLan-L Trial Investigators</creatorcontrib><creatorcontrib>on behalf of the LixiLan-L Trial Investigators</creatorcontrib><title>Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial</title><title>Diabetes care</title><addtitle>Diabetes Care</addtitle><description>This study was conducted to demonstrate the efficacy and safety of LixiLan (iGlarLixi), a novel, titratable, fixed-ratio combination of insulin glargine (iGlar) (100 units) and lixisenatide, compared with iGlar in patients with type 2 diabetes inadequately controlled on basal insulin with or without up to two oral glucose-lowering agents.
After a 6-week run-in when iGlar was introduced and/or further titrated, and oral antidiabetic drugs other than metformin were stopped, 736 basal insulin-treated patients (mean diabetes duration 12 years, BMI 31 kg/m
) were randomized 1:1 to open-label, once-daily iGlarLixi or iGlar, both titrated to fasting plasma glucose <100 mg/dL (<5.6 mmol/L) up to a maximum dose of 60 units/day. The primary outcome was change in HbA
levels at 30 weeks.
HbA
decreased from 8.5% (69 mmol/mol) to 8.1% (65 mmol/mol) during the run-in period. After randomization, iGlarLixi showed greater reductions in HbA
from baseline compared with iGlar (-1.1% vs. -0.6%, P < 0.0001), reaching a mean final HbA
of 6.9% (52 mmol/mol) compared with 7.5% (58 mmol/mol) for iGlar. HbA
<7.0% (53 mmol/mol) was achieved in 55% of iGlarLixi patients compared with 30% on iGlar. Mean body weight decreased by 0.7 kg with iGlarLixi and increased by 0.7 kg with iGlar (1.4 kg difference, P < 0.0001). Documented symptomatic hypoglycemia (≤70 mg/dL) was comparable between groups. Mild gastrointestinal adverse effects were very low but more frequent with iGlarLixi.
Compared with iGlar, a substantially higher proportion of iGlarLixi-treated patients achieved glycemic targets with a beneficial effect on body weight, no additional risk of hypoglycemia, and low levels of gastrointestinal adverse effects in inadequately controlled, basal insulin-treated, long-standing type 2 diabetes.</description><subject>Aged</subject><subject>Blood Glucose - metabolism</subject><subject>Body Mass Index</subject><subject>Body Weight</subject><subject>Clinical trials</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Combinations</subject><subject>Drug Evaluation, Preclinical</subject><subject>Endpoint Determination</subject><subject>Female</subject><subject>Glycated Hemoglobin A - metabolism</subject><subject>Humans</subject><subject>Hypoglycemic Agents - administration & dosage</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Insulin</subject><subject>Insulin - therapeutic use</subject><subject>Insulin Glargine - administration & dosage</subject><subject>Insulin Glargine - therapeutic use</subject><subject>Male</subject><subject>Medical treatment</subject><subject>Metformin - therapeutic use</subject><subject>Middle Aged</subject><subject>Peptides - administration & dosage</subject><subject>Peptides - therapeutic use</subject><subject>Pharmaceuticals</subject><subject>Side effects</subject><subject>Treatment Outcome</subject><issn>0149-5992</issn><issn>1935-5548</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkctu1TAQhiMEoofCghdAltiARMCXXGx2cGhLpSBQCetoYk_AleOc2onU8Jw8EA69LFjZmvnm0y_9Wfac0bdciPqd0azKWaHKB9mOKVHmZVnIh9mOplleKsWPsicxXlJKi0LKx9kRr6uSqrreZX9OhsFq0CsBb8h3GHBeyTSQxl7bBvwbAqS1c4AZeofk1F6jyS9gthPZT2Nv_fb128G5j4uznpw5CD-tR_LNLfGfJuJGGSRp264HJJx8stDjjDFdgcGrBWZ0azL6OUzOoSHJ-REiuHvtlu4LzsMURuvfk_YX3kXMG3KRttNof6fDNlhwT7NHA7iIz27f4-zH6Um7_5w3X8_O9x-aXBesmHNRc6akplxSjYwz3qMSRtKeK8P7fkhTWVJZ88HU1HDdUy0oiKpXCBxUIY6zVzfeQ5iuFoxzN9qo0TnwOC2xY7KoZa1oVSX05X_o5bQEn9IlSkglS1GxRL2-oXSYYgw4dIdgRwhrx2i3Vd1tVXdb1Yl9cWtc-hHNPXnXrfgLJ2WlgA</recordid><startdate>20161101</startdate><enddate>20161101</enddate><creator>Aroda, Vanita R</creator><creator>Rosenstock, Julio</creator><creator>Wysham, Carol</creator><creator>Unger, Jeffrey</creator><creator>Bellido, Diego</creator><creator>González-Gálvez, Guillermo</creator><creator>Takami, Akane</creator><creator>Guo, Hailing</creator><creator>Niemoeller, Elisabeth</creator><creator>Souhami, Elisabeth</creator><creator>Bergenstal, Richard M</creator><general>American Diabetes Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20161101</creationdate><title>Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial</title><author>Aroda, Vanita R ; Rosenstock, Julio ; Wysham, Carol ; Unger, Jeffrey ; Bellido, Diego ; González-Gálvez, Guillermo ; Takami, Akane ; Guo, Hailing ; Niemoeller, Elisabeth ; Souhami, Elisabeth ; Bergenstal, Richard M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c414t-372198c0280ce1212be93d80b29d2bbf0ce850872fd70d2cb0c30a36b9ea2a943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Aged</topic><topic>Blood Glucose - metabolism</topic><topic>Body Mass Index</topic><topic>Body Weight</topic><topic>Clinical trials</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Combinations</topic><topic>Drug Evaluation, Preclinical</topic><topic>Endpoint Determination</topic><topic>Female</topic><topic>Glycated Hemoglobin A - metabolism</topic><topic>Humans</topic><topic>Hypoglycemic Agents - administration & dosage</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Insulin</topic><topic>Insulin - therapeutic use</topic><topic>Insulin Glargine - administration & dosage</topic><topic>Insulin Glargine - therapeutic use</topic><topic>Male</topic><topic>Medical treatment</topic><topic>Metformin - therapeutic use</topic><topic>Middle Aged</topic><topic>Peptides - administration & dosage</topic><topic>Peptides - therapeutic use</topic><topic>Pharmaceuticals</topic><topic>Side effects</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aroda, Vanita R</creatorcontrib><creatorcontrib>Rosenstock, Julio</creatorcontrib><creatorcontrib>Wysham, Carol</creatorcontrib><creatorcontrib>Unger, Jeffrey</creatorcontrib><creatorcontrib>Bellido, Diego</creatorcontrib><creatorcontrib>González-Gálvez, Guillermo</creatorcontrib><creatorcontrib>Takami, Akane</creatorcontrib><creatorcontrib>Guo, Hailing</creatorcontrib><creatorcontrib>Niemoeller, Elisabeth</creatorcontrib><creatorcontrib>Souhami, Elisabeth</creatorcontrib><creatorcontrib>Bergenstal, Richard M</creatorcontrib><creatorcontrib>LixiLan-L Trial Investigators</creatorcontrib><creatorcontrib>on behalf of the LixiLan-L Trial Investigators</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aroda, Vanita R</au><au>Rosenstock, Julio</au><au>Wysham, Carol</au><au>Unger, Jeffrey</au><au>Bellido, Diego</au><au>González-Gálvez, Guillermo</au><au>Takami, Akane</au><au>Guo, Hailing</au><au>Niemoeller, Elisabeth</au><au>Souhami, Elisabeth</au><au>Bergenstal, Richard M</au><aucorp>LixiLan-L Trial Investigators</aucorp><aucorp>on behalf of the LixiLan-L Trial Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial</atitle><jtitle>Diabetes care</jtitle><addtitle>Diabetes Care</addtitle><date>2016-11-01</date><risdate>2016</risdate><volume>39</volume><issue>11</issue><spage>1972</spage><epage>1980</epage><pages>1972-1980</pages><issn>0149-5992</issn><eissn>1935-5548</eissn><coden>DICAD2</coden><abstract>This study was conducted to demonstrate the efficacy and safety of LixiLan (iGlarLixi), a novel, titratable, fixed-ratio combination of insulin glargine (iGlar) (100 units) and lixisenatide, compared with iGlar in patients with type 2 diabetes inadequately controlled on basal insulin with or without up to two oral glucose-lowering agents.
After a 6-week run-in when iGlar was introduced and/or further titrated, and oral antidiabetic drugs other than metformin were stopped, 736 basal insulin-treated patients (mean diabetes duration 12 years, BMI 31 kg/m
) were randomized 1:1 to open-label, once-daily iGlarLixi or iGlar, both titrated to fasting plasma glucose <100 mg/dL (<5.6 mmol/L) up to a maximum dose of 60 units/day. The primary outcome was change in HbA
levels at 30 weeks.
HbA
decreased from 8.5% (69 mmol/mol) to 8.1% (65 mmol/mol) during the run-in period. After randomization, iGlarLixi showed greater reductions in HbA
from baseline compared with iGlar (-1.1% vs. -0.6%, P < 0.0001), reaching a mean final HbA
of 6.9% (52 mmol/mol) compared with 7.5% (58 mmol/mol) for iGlar. HbA
<7.0% (53 mmol/mol) was achieved in 55% of iGlarLixi patients compared with 30% on iGlar. Mean body weight decreased by 0.7 kg with iGlarLixi and increased by 0.7 kg with iGlar (1.4 kg difference, P < 0.0001). Documented symptomatic hypoglycemia (≤70 mg/dL) was comparable between groups. Mild gastrointestinal adverse effects were very low but more frequent with iGlarLixi.
Compared with iGlar, a substantially higher proportion of iGlarLixi-treated patients achieved glycemic targets with a beneficial effect on body weight, no additional risk of hypoglycemia, and low levels of gastrointestinal adverse effects in inadequately controlled, basal insulin-treated, long-standing type 2 diabetes.</abstract><cop>United States</cop><pub>American Diabetes Association</pub><pmid>27650977</pmid><doi>10.2337/dc16-1495</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0149-5992 |
| ispartof | Diabetes care, 2016-11, Vol.39 (11), p.1972-1980 |
| issn | 0149-5992 1935-5548 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1847879066 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Aged Blood Glucose - metabolism Body Mass Index Body Weight Clinical trials Diabetes Diabetes Mellitus, Type 2 - drug therapy Dose-Response Relationship, Drug Drug Combinations Drug Evaluation, Preclinical Endpoint Determination Female Glycated Hemoglobin A - metabolism Humans Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - therapeutic use Insulin Insulin - therapeutic use Insulin Glargine - administration & dosage Insulin Glargine - therapeutic use Male Medical treatment Metformin - therapeutic use Middle Aged Peptides - administration & dosage Peptides - therapeutic use Pharmaceuticals Side effects Treatment Outcome |
| title | Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T05%3A27%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20Safety%20of%20LixiLan,%20a%20Titratable%20Fixed-Ratio%20Combination%20of%20Insulin%20Glargine%20Plus%20Lixisenatide%20in%20Type%202%20Diabetes%20Inadequately%20Controlled%20on%20Basal%20Insulin%20and%20Metformin:%20The%20LixiLan-L%20Randomized%20Trial&rft.jtitle=Diabetes%20care&rft.au=Aroda,%20Vanita%20R&rft.aucorp=LixiLan-L%20Trial%20Investigators&rft.date=2016-11-01&rft.volume=39&rft.issue=11&rft.spage=1972&rft.epage=1980&rft.pages=1972-1980&rft.issn=0149-5992&rft.eissn=1935-5548&rft.coden=DICAD2&rft_id=info:doi/10.2337/dc16-1495&rft_dat=%3Cproquest_cross%3E4248783501%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1838985361&rft_id=info:pmid/27650977&rfr_iscdi=true |